Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q3 2020 · 10-Q
Revenue$145.20M$145.20M−22.1% vs Q3 2019 Net Income-$15.20M-$15.20MN/M vs Q3 2019 EPS Diluted-$0.20-$0.20N/M vs Q3 2019 Operating Income-$39,600,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Free Cash Flowderived-$60,800,000N/M Margins · derivedOperating margin-27.3%−16.1 pt vs Q3 2019
Net margin-10.5%+0.6 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 9, 2020 · 40 d after period end